Quarterly report pursuant to Section 13 or 15(d)

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Loss Contingencies [Line Items]    
Professional Fees $ 639,405 $ 769,497
Research and Development Expense $ 254,837 73,954
Chairman And CEO [Member]    
Loss Contingencies [Line Items]    
Description of nature and effects The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company  
Employment Agreements [Member]    
Loss Contingencies [Line Items]    
Accrued Salaries, Current $ 346,592  
License Agreement [Member]    
Loss Contingencies [Line Items]    
Research and Development Expense   73,954
License Agreement [Member] | IGL Pharma Inc [Member]    
Loss Contingencies [Line Items]    
Other Expenses   60,000
Stock Issued During Period, Shares, New Issues 12,500  
Royalty percentage 4.50%  
Sublicense percentage 5.00%  
Payment for license fees   60,000
Professional Fees $ 8,500  
License Agreement [Member] | IGL Pharma Inc [Member] | Upon Commercialization [Member]    
Loss Contingencies [Line Items]    
Other Expenses 2,000,000  
License Agreement [Member] | IGL Pharma Inc [Member] | Maximum [Member]    
Loss Contingencies [Line Items]    
Other Expenses 410,000  
Consulting Agreement [Member]    
Loss Contingencies [Line Items]    
Research and Development Expense 25,500 $ 73,954
Consulting Agreement [Member] | IGL Pharma Inc [Member]    
Loss Contingencies [Line Items]    
Other Expenses 9,355  
Payments for Rent $ 8,500